The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer (NCT00542191).
Stephen Tiley
No relevant relationships to disclose
Rachel Elizabeth Raab
No relevant relationships to disclose
Lisa Sheri Bellin
No relevant relationships to disclose
Jan H. Wong
No relevant relationships to disclose
Jackie Unger
No relevant relationships to disclose
Paul R. Walker
No relevant relationships to disclose